Drug Profile
Pradigastat - Anji Pharma
Alternative Names: ANJ908; LCQ 908; LCQ908-NXA; LCQ908A; Pradigastat sodiumLatest Information Update: 15 Jun 2022
Price :
$50
*
At a glance
- Originator Novartis
- Developer Anji Pharma; Novartis
- Class Aminopyridines; Antihyperglycaemics; Antihyperlipidaemics; Cyclohexanecarboxylic acids; Laxatives; Obesity therapies; Small molecules
- Mechanism of Action Diacylglycerol O acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Constipation
- No development reported Coronary artery disease; Hyperlipoproteinaemia; Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type V; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus
- Discontinued Hepatitis C
Most Recent Events
- 03 Jun 2022 Anji Pharma completes enrolment in its phase II trial for Constipation in China (PO) (NCT04620161)
- 18 May 2022 Anji Pharma completes enrolment in its phase II trial for Constipation in US and China (NCT04620161)
- 15 Apr 2021 Pradigastat licensed to Anji Pharmaceuticals in Asia, Europe and USA before April 2021